Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Codexis ( (CDXS) ) is now available.
Codexis, Inc. announced that on April 8, 2026, director Dennis Wolf resigned from the Board of Directors and from the Audit and Compensation Committees, with the company stating his departure was not due to any disagreement over operations or policies. Following his resignation, the Board moved to rebalance its classified structure, and on April 10, 2026, it orchestrated the technical resignation and immediate re-election of director Esther Martinborough, Ph.D., shifting her from Class II to Class III and confirming her committee roles, resulting in an evenly distributed Board of three directors in each of the three classes.
These governance moves are primarily administrative, aiming to maintain an orderly staggered Board structure while preserving continuity in leadership and committee oversight. For shareholders and other stakeholders, the changes signal stability in Codexis’s governance framework, as key directors and committee chairs retain their responsibilities despite the reshuffling prompted by Wolf’s departure.
The most recent analyst rating on (CDXS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Codexis stock, see the CDXS Stock Forecast page.
Spark’s Take on CDXS Stock
According to Spark, TipRanks’ AI Analyst, CDXS is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses, cash burn, and rising leverage). This is partially offset by positive technical momentum and a cautiously optimistic earnings-call backdrop driven by ECOsynthesis progress, improved margins, and solid cash runway, though valuation remains constrained by negative earnings.
To see Spark’s full report on CDXS stock, click here.
More about Codexis
Codexis, Inc. operates in the biotechnology sector, focusing on the discovery, development and application of engineered enzymes. The company’s technologies are used to enable more efficient and sustainable manufacturing processes across pharmaceuticals and other industries, positioning Codexis within the broader market for biocatalysis and enzyme engineering solutions.
Average Trading Volume: 2,311,240
Technical Sentiment Signal: Sell
Current Market Cap: $203.5M
Learn more about CDXS stock on TipRanks’ Stock Analysis page.